Adrenocortical Carcinoma, Advanced Solid Tumours, Breast Cancer, Cervical Cancer, Endometrial Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), HER2-negative Breast Cancer, Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Uveal Melanoma
Conditions
Keywords
225-Ac Labelled Humanized Monoclonal Antibody Against IGF-1R, [225Ac]-FPI-1434, IGF-IR Targeted Alpha Therapeutic, IGF-IR Radioligand Therapy, Radiopharmaceuticals
Brief summary
This is a first-in-human Phase 1/2, non-randomized, multi-centre, open-label clinical study designed to investigate safety, tolerability, PK, and preliminary anti-tumour activity of \[225Ac\]-FPI-1434 (radioimmuno-therapeutic agent) in patients with solid tumours that demonstrate uptake of \[111In\]-FPI-1547 (radioimmuno-imaging agent), and to establish the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of repeat doses of \[225Ac\]-FPI-1434 Injection in patients with solid tumours that demonstrate uptake of \[111In\]-FPI-1547 (radioimmuno-imaging agent).
Detailed description
This study consists of a Phase 1 portion and a Phase 2 portion. Phase 1 includes the following cohorts: Single dose-ascending cohorts and Multi- dose ascending cohorts of \[225Ac\]-FPI-1434 and Multi- dose ascending cohorts evaluating administration of FPI-1175 (cold antibody), followed by, \[225Ac\]-FPI-1434 (cold + hot), with cycles repeating every 42 days. And Cold Antibody Sub-study evaluating administration of ascending doses of FPI-1175 followed by \[111In\]-FPI-1547. The Phase 2 will evaluate \[111In\]-FPI-1547 and \[225Ac\]-FPI-1434 with or without FPI-1175 in tumour-specific cohorts. The decision to utilize FPI-1175 in the Phase 2 portion of the study will be determined based on Phase 1 data, including safety, tolerability, pharmacokinetic and dosimetry results.
Interventions
DRUG[111In]-FPI-1547 Injection
\[111In\]-FPI-1547 is a targeted radioimmuno-imaging agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Indium-111, a radionuclide. Patients will receive \[111In\]-FPI-1547 Injection of 185 MBq (5 mCi) for imaging.
DRUG[225Ac]-FPI-1434 Injection multi-dose
\[225Ac\]-FPI-1434 is a targeted alpha radioimmuno-therapeutic agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Actinium-225, an alpha-emitting radionuclide. Patients will receive multiple doses of \[225Ac\]-FPI-1434 Injection. Dose is per cohort assignment.
BIOLOGICALFPI-1175 Infusion
FPI-1175 is an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody without a radioisotope. Patients will receive FPI-1175 Infusion at a dose per cohort assignment.
DRUG[225Ac]-FPI-1434 Injection single-dose
\[225Ac\]-FPI-1434 is a targeted alpha radioimmuno-therapeutic agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate, and Actinium-225, an alpha-emitting radionuclide. Patients will receive a single dose of \[225\]-FPI-1434 Injection. Dose is per cohort assignment.
Sponsors
Fusion Pharmaceuticals Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Pathologically documented, definitively diagnosed, advanced solid tumour that is refractory to all standard treatment, for which no standard treatment is available, or it is contraindicated, or the patient refuses standard therapy. 2. Measurable or evaluable disease in accordance with RECIST 1.1. 3. Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1. 4. Life expectancy of greater than 3 months as judged by the treating physician. 5. Available tumour tissue (either archival or fresh biopsy) for IGF-1R immunohistochemistry. Submission of the tissue is not required prior to enrollment. 6. Adequate heart, kidney, and liver function 7. Adequate bone marrow reserves 8. Ability to understand and the willingness to sign a written informed consent document. Phase 2 Specific 9. Histologically and/or cytologically documented diagnosis of locally advanced, inoperable, metastatic, or recurrent solid tumour types: endometrial, cervical, ovarian, TNBC, HER 2-negative breast, HNSCC, ACC, or uveal melanoma. 10. Have measurable disease per RECIST 1.1 Failure to respond to standard systemic therapy, or for whom standard or curative systemic therapy does not exist or is not tolerable. Imaging Eligibility 11. Prior to the initial \[225Ac\]-FPI-1434 cycle: Sufficient target expression in at least 1 lesion following \[111In\]-FPI-1547 and SPECT imaging.
Exclusion criteria
1. Systemic therapeutic radiopharmaceutical within 6 months prior to enrollment into this study. 2. Contraindications to or inability to perform the required imaging procedures in this study (e.g., inability to lay flat during scan time) 3. Uncontrolled brain metastasis, including but not limited to the need for treatment with steroids, surgery or radiation therapy. 4. Anticancer therapy (including investigational agents) or external beam radiation therapy within 14 days of the dosing of \[111In\]-FPI-1547 5. Has known additional malignancy that is progressing or has required active treatment within the past 3 years. Patients with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ (e.g., breast cancer, cervical cancer, prostate) that have undergone potentially curative therapy are not excluded. 6. Residual CTCAE ≥ Grade 2 side effects of prior therapy, with the exception of residual grade 2 alopecia. 7. Prior organ transplantation, including stem cell transplantation. 8. Any prior treatment with nitrosoureas or actinomycin-D. 9. Clinically relevant levels of protein in the urine 10. Known or suspected allergies or contraindications to the Investigational Products or any component of the investigational drug formulation. 11. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, diabetes, or psychiatric illness/social situations that would limit compliance with study requirements. 12. Received \> 20 Gy prior radiation to large areas of the bone marrow
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Single-Dose Escalation: Incidence of dose limiting toxicities (DLTs). | 8 weeks. | Phase 1 |
| Multi-Dose Escalation: Incidence of DLTs. | 6 weeks. | Phase 1 |
| Evaluate anti-tumour activity of [225Ac]-FPI-1434 regimen | Approximately one year post final [225Ac]-FPI-1434 injection. | Phase 2 |
| Objective response rate (ORR) RECIST v1.1. | Approximately one year post final [225Ac]-FPI-1434 Injection. | Phase 2 |
| Dose Escalation: Incidence of clinically significant clinical laboratory abnormalities. | Approximately one year post final [225Ac]-FPI-1434 Injection. | Phase 1 |
| Dose Escalation: Changes in electrocardiogram (ECG) parameters (PR, QRS, QT, and QTc intervals). | 4 weeks post final [225Ac]-FPI-1434 Injection. | Phase 1 |
| Cold Antibody Sub-Study: Changes in uptake of [111In]-FPI-1547 Injection following FPI-1175 Infusion in selected regions of interest on SPECT/CT images. | Within two weeks of the first [111In]-FPI-1547 Injection. | Phase 1 |
| Cold Antibody Sub-Study: Changes in radiation dose estimates for selected tissues, organs and whole body both for [111In]-FPI-1547 and [225Ac]-FPI-1434 Injection at various dose levels following FPI-1175 Infusion. | Within two weeks of the first [111In]-FPI-1547 Injection. | Phase 1 |
| Dose Escalation: Incidence of adverse events (AEs). | Approximately one year post final [225Ac]-FPI-1434 Injection. | Phase 1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Dose Escalation: Changes in the corrected QT (QTc) interval in milliseconds after [225Ac]-FPI-1434 treatment, compared to baseline. | Approximately 24 hours from the time of [225Ac]-FPI-1434 Injection administration. | Phase 1 and 2 |
| Dose Escalation and Cold-Antibody Sub-Study: Changes in human growth hormone (hGh) following [111In]-FPI-1547 Injection and [225Ac]-FPI-1434 Injection. | 4 weeks post final [225Ac]-FPI-1434 Injection. | Phase 1 and 2 |
| Dose Escalation and Cold-Antibody Sub-Study: Changes in insulin-like growth factor 1 (IGF-1) following [111In]-FPI-1547 Injection and [225Ac]-FPI-1434 Injection. | 4 weeks post final [225Ac]-FPI-1434 Injection. | Phase 1 and 2 |
| Dose Escalation and Cold-Antibody Sub-Study: Changes in insulin-like growth factor binding protein 3 (IGFBP-3) following [111In]-FPI-1547 Injection and [225Ac]-FPI-1434 Injection. | 4 weeks post final [225Ac]-FPI-1434 Injection. | Phase 1 and 2 |
| Cold Antibody Sub-Study: Incidence of AEs. | Approximately one year post final [225Ac]-FPI-1434 Injection. | Phase 1 and 2 |
| Cold Antibody Sub-Study: Incidence of clinically significant clinical laboratory abnormalities. | Approximately one year post final [225Ac]-FPI-1434 Injection. | Phase 1 and 2 |
| Cold Antibody Sub-Study: Changes in ECG parameters (PR, QRS, QT, and QTc intervals). | 4 weeks post final [225Ac]-FPI-1434 Injection. | Phase 1 and 2 |
| Dose Escalation and Cold-Antibody Sub-Study: Duration of response (DoR). | Approximately one year post final [225Ac]-FPI-1434 Injection. | Phase 1 and 2 |
| Dose Escalation and Cold-Antibody Sub-Study: Progression free survival (PFS). | Approximately one year post final [225Ac]-FPI-1434 Injection. | Phase 1 and 2 |
| Dose Escalation and Cold-Antibody Sub-Study: Time to Progression (TTP). | Approximately one year post final [225Ac]-FPI-1434 Injection. | Phase 1 and 2 |
| Dose Escalation and Cold-Antibody Sub-Study: Disease control rate (DCR). | Approximately one year post final [225Ac]-FPI-1434 Injection. | Phase 1 and 2 |
| Dose Escalation and Cold-Antibody Sub-Study: Overall survival (OS). | Approximately one year post final [225Ac]-FPI-1434 Injection. | Phase 1 and 2 |
| Dose Escalation and Cold-Antibody Sub-Study: Time to response (TTR). | Approximately one year post final [225Ac]-FPI-1434 Injection. | Phase 1 and 2 |
| Dose Escalation and Cold Antibody Sub-Study: Tumour uptake of [111In]-FPI-1547 in selected regions of interest on SPECT/CT images. | Dose Escalation: Within one week of the [111In]-FPI-1547 Injection. Cold-Antibody Sub-Study: Within two weeks of the first [111In]-FPI-1547 Injection. | Phase 1 and 2 |
| Dose Escalation: Radiation doses for selected organs and whole body both for [111In]-FPI-1547 Injection and [225Ac]-FPI-1434 Injection. | Within one week of the [111In]-FPI-1547 Injection. | Phase 1 and 2 |
| Dose Escalation and Cold-Antibody Sub-Study: Changes in radiation absorbed doses for tumour lesions for [225Ac]-FPI-1434. | Dose Escalation: Within one week of the [111In]-FPI-1547 Injection. Cold-Antibody Sub-Study: Within two weeks of the first [111In]-FPI-1547 Injection. | Phase 1 and 2 |
| Dose Escalation and Cold-Antibody Sub-Study: Clearance for radioactivity and for the targeting antibody. | 4 weeks post final [225Ac]-FPI-1434 Injection. | Phase 1 and 2 |
| Dose Escalation and Cold-Antibody Sub-Study: Area under the curve (AUC) for radioactivity and for the targeting antibody. | 4 weeks post final [225Ac]-FPI-1434 Injection. | Phase 1 and 2 |
| Dose Escalation and Cold-Antibody Sub-Study: Cmax for radioactivity and for the targeting antibody. | 4 weeks post final [225Ac]-FPI-1434 Injection. | Phase 1 and 2 |
| Dose Escalation and Cold-Antibody Sub-Study: Half-life for radioactivity and for the targeting antibody. | 4 weeks post final [225Ac]-FPI-1434 Injection. | Phase 1 and 2 |
| Dose Escalation and Cold-Antibody Sub-Study: Objective response rate (ORR) (sum of complete and partial response) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or Prostate Cancer Working Group 3 (PCWG3) guidelines. | Approximately one year post final [225Ac]-FPI-1434 Injection. | Phase 1 |
Countries
Australia, Canada, United States
Outcome results
None listed